Alexion Pharmaceuticals

Healthcare | Biotechnology | USA
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates

...

Earnings: Alexion surpassed earnings expectations in the fourth quarter of 2018. Our consensus called for EPS of $1.83, and the company reported EPS of $2.14.

Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.128 billion, compared to our consensus estimate of $1.06 billion.

...

https://finance.yahoo.com/news/alexion-a...ccounter=1

Alexion (ALXN) Tops Q1 Earnings and Revenues Beat Estimates

...

Earnings: Alexion surpassed earnings expectations in the first quarter of 2019. Our consensus called for EPS of $2.19, and the company reported EPS of $2.39.

Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.14 billion, compared to our consensus estimate of $1.11 billion.

Key Stats: Soliris sales increased 20% in the quarter to $962 million.  In February 2019, the FDA granted priority review for Soliris for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) and set an action date of June 28, 2019.

2019 Guidance: The company raised its earnings and revenue guidance. The company expects earnings per share to be $9.25 to $9.45 up from its previous guidance of $9.10-$9.30. Alexion projects revenues of$4.68 to $4.75 billion up from the prior outlook of $4.63-$4.70 billion in 2019. The Zacks Consensus Estimate for earnings in 2019 is pegged at $9.31, while for sales it is $4.75 billion.

...



https://finance.yahoo.com/news/alexion-a...12865.html